Whole breast radiotherapy in the isocentric lateral decubitus position: Role of the immobilization device and table on clinical results.

CONCLUSIONS: Whole breast radiotherapy in the isocentric lateral decubitus position is well tolerated. Clinical results are comparable based on different immobilization device allowed by linear accelerators. Particularly, there was no influence of the couch on skin tolerance and cosmetic results. PMID: 31053514 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research

Related Links:

Conditions:   Breast Cancer;   Radiodermatitis;   Radiotherapy Side Effect;   Radiation Dermatitis;   Radiation Toxicity;   Radiation Injuries;   Quality of Life;   Breast Neoplasms Intervention:   Device: Photobiomodulation Sponsor:   AC Camargo Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: IMPT following IBR spared underlying organs and had low rates of acute toxicity. Reconstruction complications are more common in irradiated breasts, and reconstructive outcomes appear comparable with photon literature. Hypofractionation was associated with higher reconstruction failure rates. Further investigation of optimal dose-fractionation after IBR is needed. PMID: 31185327 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
ConclusionsTopical agents for preventive ARD are reported by patients to show different cosmetic properties. Cosmetic properties are important when choosing topical agents for ARD prevention. Recommending those with better cosmetic profiles would improve patient adherence to treatments.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
Conclusion: IOERT boost during BCS is a safe treatment option with low acute toxicity. Short-term recurrence rates are comparable to previously published data and emphasize, that IOERT as boost is an effective treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Radiation Dermatitis Interventions:   Device: Gelronate;   Other: Aloevera Sponsors:   Sheba Medical Center;   Ferring Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Dermatitis | Dermatology | Skin | Toxicology | Women